Patents by Inventor Colleen M. Craig
Colleen M. Craig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240042035Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.Type: ApplicationFiled: June 22, 2023Publication date: February 8, 2024Inventors: Xiaofeng XIONG, Debra ODINK, Colleen M. CRAIG, Christine M.N. Smith, Tracey L. McLaughlin
-
Publication number: 20240000894Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: ApplicationFiled: February 22, 2023Publication date: January 4, 2024Inventors: Tracey L. MCLAUGHLIN, Colleen M. CRAIG
-
Publication number: 20230346890Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: ApplicationFiled: February 22, 2023Publication date: November 2, 2023Inventors: Tracey L. MCLAUGHLIN, Colleen M. CRAIG
-
Patent number: 11738086Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.Type: GrantFiled: May 3, 2021Date of Patent: August 29, 2023Assignee: Eiger Biopharmaceuticals, Inc.Inventors: Xiaofeng Xiong, Debra Odink, Colleen M. Craig, Christine M. N. Smith, Tracey L. McLaughlin
-
Patent number: 11622995Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: GrantFiled: April 9, 2021Date of Patent: April 11, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Tracey L. McLaughlin, Colleen M. Craig
-
Patent number: 11617782Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: GrantFiled: April 9, 2021Date of Patent: April 4, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Tracey L. McLaughlin, Colleen M. Craig
-
Publication number: 20210338780Abstract: Methods of treating hyperinsulinemic hypoglycemia (HH), including post-bariatric hypoglycemia (PBH) are provided. In some embodiments, the method comprises administering to a subject having HH a buffered liquid formulation composition.Type: ApplicationFiled: October 15, 2019Publication date: November 4, 2021Inventors: Colleen M. CRAIG, Lisa PORTER
-
Publication number: 20210315995Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.Type: ApplicationFiled: May 3, 2021Publication date: October 14, 2021Inventors: Xiaofeng Xiong, Debra Odink, Colleen M. Craig, Christine M.N. Smith, Tracey L. McLaughlin
-
Publication number: 20210315974Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Inventors: Tracey L. MCLAUGHLIN, Colleen M. CRAIG
-
Publication number: 20210290731Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: ApplicationFiled: April 9, 2021Publication date: September 23, 2021Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Patent number: 11020484Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.Type: GrantFiled: November 21, 2017Date of Patent: June 1, 2021Assignees: Eiger BioPharmaceuticals, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Xiaofeng Xiong, Debra Odink, Colleen M. Craig, Christine M. N. Smith, Tracey L. McLaughlin
-
Patent number: 10993991Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: GrantFiled: March 9, 2020Date of Patent: May 4, 2021Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Tracey L. McLaughlin, Colleen M. Craig
-
Patent number: 10993992Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: GrantFiled: March 9, 2020Date of Patent: May 4, 2021Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Tracey L. McLaughlin, Colleen M. Craig
-
Publication number: 20200276272Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: ApplicationFiled: March 9, 2020Publication date: September 3, 2020Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Publication number: 20200276271Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: ApplicationFiled: March 9, 2020Publication date: September 3, 2020Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Patent number: 10660937Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of glucagon-like peptide-1 receptor antagonist (GLP1RA) exendin(9-39). Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery or gastrointestinal surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA exendin(9-39).Type: GrantFiled: May 23, 2016Date of Patent: May 26, 2020Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Patent number: 10639354Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery or gastrointestinal surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: GrantFiled: May 23, 2016Date of Patent: May 5, 2020Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Publication number: 20200069802Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.Type: ApplicationFiled: November 21, 2017Publication date: March 5, 2020Inventors: Xiaofeng Xiong, Debra Odink, Colleen M. Craig, Christine M.N. Smith
-
Publication number: 20180147261Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.Type: ApplicationFiled: May 23, 2016Publication date: May 31, 2018Inventors: Tracey L. McLaughlin, Colleen M. Craig
-
Publication number: 20180117122Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.Type: ApplicationFiled: May 23, 2016Publication date: May 3, 2018Inventors: Tracey L. McLaughlin, Colleen M. Craig